Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

被引:100
作者
Ashina, Messoud [1 ,2 ]
Tepper, Stewart [3 ]
Brandes, Jan Lewis [4 ,5 ]
Reuter, Uwe [6 ]
Boudreau, Guy [7 ]
Dolezil, David [8 ]
Cheng, Sunfa [9 ]
Zhang, Feng [9 ]
Lenz, Robert [9 ]
Klatt, Jan [10 ]
Mikol, Daniel D. [9 ]
机构
[1] Univ Copenhagen, Fac Med & Hlth Sci, Rigshosp Glostrup, Danish Headache Ctr, Copenhagen, Denmark
[2] Univ Copenhagen, Fac Med & Hlth Sci, Rigshosp Glostrup, Dept Neurol, Copenhagen, Denmark
[3] Geisel Sch Med Dartmouth, Hanover, NH USA
[4] Vanderbilt Univ, Nashville Neurosci Grp, 221 Kirkland Hall, Nashville, TN 37235 USA
[5] Vanderbilt Univ, Dept Neurol, 221 Kirkland Hall, Nashville, TN 37235 USA
[6] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[7] Univ Hosp Ctr Montreal, Neurol Dept, Headache Unit, Montreal, PQ, Canada
[8] DADO Med Sro, Prague Headache Ctr, Prague, Czech Republic
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
[10] Novartis Pharma AG, Basel, Switzerland
关键词
Erenumab; chronic migraine; clinical trial of prophylactic migraine treatment; prior preventive treatment failure; prior prophylactic treatment failure; CONTROLLED PHASE; TRIAL; ONABOTULINUMTOXINA;
D O I
10.1177/0333102418788347
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic migraine. Here, we evaluated efficacy and safety of monthly erenumab (70mg or 140mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s) ( 1,2 prior failed medication categories) and in patients who had never failed. Methods Subgroup analyses evaluated change from baseline in monthly migraine days; achievement of 50% and 75% reduction in monthly migraine days; and change in monthly acute migraine-specific medication days. Adverse events were evaluated for each subgroup. Results Treatment with both doses of erenumab resulted in greater reductions in monthly migraine days (primary endpoint) at Month 3 (treatment difference [95% CI], never failed subgroup: -2.2 [-4.1, -0.3] for 70mg and -0.5 [-2.4, 1.5] for 140mg; 1 prior failed medication categories subgroup: -2.5 [-3.8, -1.2], for 70mg and -3.3 [-4.6, -2.1] for 140mg;2 prior failed medication categories subgroup: -2.7 [-4.2, -1.2], for 70mg and -4.3 [-5.8, -2.8] for 140mg). Similar results were observed in the monthly acute migraine-specific medication days endpoint, and in the achievement of 50% and 75% reduction in monthly migraine days. There were no new or unexpected safety issues. Conclusion Erenumab showed consistent efficacy in chronic migraine patients who had failed prior preventive treatments and was well tolerated across subgroups.
引用
收藏
页码:1611 / 1621
页数:11
相关论文
共 12 条
[1]  
[Anonymous], 2017, Cephalalgia, V37, P1, DOI 10.1177/0333102417719571
[2]  
Aurora SK, 2010, CEPHALALGIA, V30, P793, DOI 10.1177/0333102410364676
[3]   OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial [J].
Diener, H. C. ;
Dodick, D. W. ;
Aurora, S. K. ;
Turkel, C. C. ;
DeGryse, R. E. ;
Lipton, R. B. ;
Silberstein, S. D. ;
Brin, M. F. .
CEPHALALGIA, 2010, 30 (07) :804-814
[4]   The importance of placebo in headache research [J].
Diener, H-C ;
Schorn, C. F. ;
Bingel, U. ;
Dodick, D. W. .
CEPHALALGIA, 2008, 28 (10) :1003-1011
[5]   Clinically significant drug interactions with agents specific for migraine attacks [J].
Eadie, MJ .
CNS DRUGS, 2001, 15 (02) :105-118
[6]   Preventive treatment in migraine and the new US guidelines [J].
Estemalik, E. ;
Tepper, S. .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 :709-720
[7]   Adherence to oral migraine-preventive medications among patients with chronic migraine [J].
Hepp, Zsolt ;
Dodick, David W. ;
Varon, Sepideh F. ;
Gillard, Patrick ;
Hansen, Ryan N. ;
Devine, Emily B. .
CEPHALALGIA, 2015, 35 (06) :478-488
[8]   Defining the Differences Between Episodic Migraine and Chronic Migraine [J].
Katsarava, Zaza ;
Buse, Dawn C. ;
Manack, Aubrey N. ;
Lipton, Richard B. .
CURRENT PAIN AND HEADACHE REPORTS, 2012, 16 (01) :86-92
[9]   Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor [J].
Shi, Licheng ;
Lehto, Sonya G. ;
Zhu, Dawn X. D. ;
Sun, Hong ;
Zhang, Jianhua ;
Smith, Brian P. ;
Immke, David C. ;
Wild, Kenneth D. ;
Xu, Cen .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 356 (01) :223-231
[10]   Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial [J].
Silberstein, Stephen D. ;
Lipton, Richard B. ;
Dodick, David W. ;
Freitag, Frederick G. ;
Ramadan, Nabih ;
Mathew, Ninan ;
Brandes, Jan L. ;
Bigal, Marcelo ;
Saper, Joel ;
Ascher, Steven ;
Jordan, Donna M. ;
Greenberg, Steven J. ;
Hulihan, Joseph .
HEADACHE, 2007, 47 (02) :170-180